Use of calcium channel blockers and risk of hospitalized gastrointestinal tract bleeding

被引:43
作者
Kaplan, RC
Heckbert, SR
Koepsell, TD
Rosendaal, FR
Psaty, BM
机构
[1] Univ Washington, Cardiovasc Hlth Res Unit, Seattle, WA 98195 USA
[2] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA
[3] Univ Washington, Dept Med, Seattle, WA 98195 USA
[4] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA
[5] Univ Leiden Hosp, Dept Clin Epidemiol, NL-2300 RC Leiden, Netherlands
关键词
D O I
10.1001/archinte.160.12.1849
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: We conducted a case-control study of the association between calcium channel blocker use and gastrointestinal (GI) tract bleeding in hypertensive members of a health maintenance organization. Methods: Case patients (n=174) were treated hypertensive health maintenance organization members hospitalized for GI tract bleeding between January 1992 and December 1994. Case patients were identified using computerized diagnosis codes and were confirmed by medical record review. Control subjects (n=771) were treated hypertensive members selected from ongoing studies at the health maintenance organization. Computerized pharmacy data and medical records were used to assess medication use and other risk factors for GI tract bleeding. Results: Compared with P-blocker users, calcium channel blocker users had an age-, sex- and calendar year-adjusted relative risk (RR) of GI tract bleeding of 2.60 (95% confidence interval [CI], 1.71-3.96). The RR associated with calcium channel blocker use was 2.05 (95% CI, 1.33-3.17) after further adjustment for number of recent visits, diastolic blood pressure, chronic congestive heart failure, and duration of hypertension. No significant dose-response relationship was observed. Compared with P-blocker users, angiotensin-converting enzyme inhibitor users had an RR of 1.22 (95% CI, 0.75-1.97). Calcium channel blocker use tended to be more strongly associated with risk of lower GI tract bleeding (RR, 2.56; 95% CI, 1.08-6.05) than with risk of upper GI tract bleeding (RR, 1.54; 95% CI, 0.91-2.59) or peptic ulcer-related bleeding (RR, 1.17; 95% CI, 0.62-2.21), although these results were compatible with chance. Conclusions: Calcium channel blocker use might be associated with an elevated risk of GI tract bleeding. These findings require confirmation in randomized studies.
引用
收藏
页码:1849 / 1855
页数:7
相关论文
共 28 条
[1]  
Allescher H.-D., 1993, Dysphagia, V8, P125, DOI 10.1007/BF02266993
[2]  
[Anonymous], 1999, International classification of diseases, clinical modification: Ninth revision, tenth edition
[3]   Nifedipine and verapamil inhibit the sigmoid colon myoelectric response to eating in healthy volunteers [J].
Bassotti, G ;
Calcara, C ;
Annese, V ;
Fiorella, S ;
Roselli, P ;
Morelli, A .
DISEASES OF THE COLON & RECTUM, 1998, 41 (03) :377-380
[4]   COMPARATIVE INHIBITORY EFFECTS OF DIHYDROPYRIDINES ON PLATELET-AGGREGATION, CALCIUM-UPTAKE AND CYCLIC-AMP CONCENTRATION [J].
BLACHE, D ;
OJEDA, C .
PHARMACOLOGY, 1992, 45 (05) :250-259
[5]   Rationale and design for the antihypertensive and lipid lowering treatment to prevent heart attack trial (ALLHAT) [J].
Davis, BR ;
Cutler, JA ;
Gordon, DJ ;
Furberg, CD ;
Wright, JT ;
Cushman, WC ;
Grimm, RH ;
LaRosa, J ;
Whelton, PK ;
Perry, HM ;
Alderman, MH ;
Ford, CE ;
Oparil, S ;
Francis, C ;
Proschan, M ;
Pressel, S ;
Black, HR ;
Hawkins, CM .
AMERICAN JOURNAL OF HYPERTENSION, 1996, 9 (04) :342-360
[6]  
DOLELRY CT, 1991, AM J HYPERTENS, V4, pS88
[7]   Major upper gastrointestinal bleeding and the use of calcium channel blockers [J].
Kelly, JP ;
Laszlo, A ;
Kaufman, DW ;
Sundstrom, A ;
Shapiro, S .
LANCET, 1999, 353 (9152) :559-559
[8]   Safety of long-acting dihydropyridine calcium channel blockers in hypertensive patients [J].
Kloner, RA ;
Vetrovec, GW ;
Materson, BJ ;
Levenstein, M .
AMERICAN JOURNAL OF CARDIOLOGY, 1998, 81 (02) :163-169
[9]   EFFECT OF VERAPAMIL ON HUMAN INTESTINAL TRANSIT [J].
KREVSKY, B ;
MAURER, AH ;
NIEWIAROWSKI, T ;
COHEN, S .
DIGESTIVE DISEASES AND SCIENCES, 1992, 37 (06) :919-924
[10]   INHIBITORY EFFECT OF CLENTIAZEM (TA-3090) ON PLATELET-AGGREGATION - ALONE AND IN COMBINATION WITH ASPIRIN OR TICLOPIDINE [J].
ODAWARA, A ;
KATOH, M ;
KARASAWA, T ;
TAMURA, K ;
SASAKI, Y .
THROMBOSIS RESEARCH, 1994, 75 (02) :109-119